Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANL NASDAQ:CRDF NASDAQ:IMMX NASDAQ:STTK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANLAdlai Nortye$11.94+5.7%$11.65$0.88▼$17.25$452M1.23180,043 shs105,593 shsCRDFCardiff Oncology$1.90+3.3%$1.69$1.48▼$4.56$125.80M1.36999,979 shs782,719 shsIMMXImmix Biopharma$9.00+1.8%$9.32$1.87▼$11.61$481M0.121.30 million shs963,861 shsSTTKShattuck Labs$5.95-0.3%$6.67$0.71▼$8.33$456.25M1.18540,279 shs1.04 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANLAdlai Nortye+5.66%+0.17%-15.26%+51.91%+557.85%CRDFCardiff Oncology+3.26%+6.74%+17.28%-2.06%-40.44%IMMXImmix Biopharma+1.81%+2.51%+4.29%+11.52%+361.54%STTKShattuck Labs-0.34%-2.46%-16.08%+51.79%+472.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANLAdlai Nortye$11.94+5.7%$11.65$0.88▼$17.25$452M1.23180,043 shs105,593 shsCRDFCardiff Oncology$1.90+3.3%$1.69$1.48▼$4.56$125.80M1.36999,979 shs782,719 shsIMMXImmix Biopharma$9.00+1.8%$9.32$1.87▼$11.61$481M0.121.30 million shs963,861 shsSTTKShattuck Labs$5.95-0.3%$6.67$0.71▼$8.33$456.25M1.18540,279 shs1.04 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANLAdlai Nortye+5.66%+0.17%-15.26%+51.91%+557.85%CRDFCardiff Oncology+3.26%+6.74%+17.28%-2.06%-40.44%IMMXImmix Biopharma+1.81%+2.51%+4.29%+11.52%+361.54%STTKShattuck Labs-0.34%-2.46%-16.08%+51.79%+472.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANLAdlai Nortye 2.60Moderate Buy$24.25103.10% UpsideCRDFCardiff Oncology 2.57Moderate Buy$10.10431.58% UpsideIMMXImmix Biopharma 2.50Moderate Buy$19.50116.67% UpsideSTTKShattuck Labs 2.67Moderate Buy$13.00118.49% UpsideCurrent Analyst Ratings BreakdownLatest CRDF, IMMX, ANL, and STTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2026ANLAdlai Nortye OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$32.005/22/2026IMMXImmix Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.005/19/2026STTKShattuck Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026CRDFCardiff Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/14/2026ANLAdlai Nortye JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$22.005/8/2026STTKShattuck Labs WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$8.00 ➝ $11.004/27/2026STTKShattuck Labs Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight4/21/2026IMMXImmix Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ANLAdlai Nortye HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$16.00 ➝ $20.004/20/2026STTKShattuck Labs HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $18.003/30/2026IMMXImmix Biopharma MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$14.00 ➝ $15.00(Data available from 5/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANLAdlai Nortye$5M95.52N/AN/A($0.21) per share-56.86CRDFCardiff Oncology$525K247.43N/AN/A$0.51 per share3.73IMMXImmix BiopharmaN/AN/AN/AN/A$1.55 per shareN/ASTTKShattuck Labs$1M456.25N/AN/A$1.25 per share4.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANLAdlai Nortye-$35.53MN/AN/AN/AN/AN/AN/AN/A8/6/2026 (Estimated)CRDFCardiff Oncology-$45.85M-$0.67N/AN/AN/A-8,527.43%-95.51%-71.47%8/4/2026 (Estimated)IMMXImmix Biopharma-$29.44M-$0.92N/AN/AN/AN/A-73.24%-59.20%6/3/2026 (Estimated)STTKShattuck Labs-$48.81M-$0.63N/AN/AN/AN/A-60.73%-55.75%8/13/2026 (Estimated)Latest CRDF, IMMX, ANL, and STTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026Q1 2026IMMXImmix Biopharma-$0.2084N/AN/AN/AN/AN/A5/14/2026Q1 2026CRDFCardiff Oncology-$0.13-$0.18-$0.05-$0.18$0.09 million$0.04 million5/7/2026Q1 2026IMMXImmix Biopharma-$0.1909-$0.18+$0.0109-$0.18N/AN/A5/7/2026Q1 2026STTKShattuck Labs-$0.14-$0.13+$0.01-$0.13N/AN/A3/25/2026Q4 2025IMMXImmix Biopharma-$0.16-$0.28-$0.12-$0.28N/AN/A3/5/2026Q4 2025STTKShattuck Labs-$0.12-$0.12N/A-$0.12$0.17 million($1.00) millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANLAdlai NortyeN/AN/AN/AN/AN/ACRDFCardiff OncologyN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANLAdlai NortyeN/A0.650.65CRDFCardiff OncologyN/A3.273.27IMMXImmix BiopharmaN/A8.758.75STTKShattuck LabsN/A22.0722.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANLAdlai Nortye35.21%CRDFCardiff Oncology16.29%IMMXImmix Biopharma11.26%STTKShattuck Labs58.74%Insider OwnershipCompanyInsider OwnershipANLAdlai NortyeN/ACRDFCardiff Oncology7.70%IMMXImmix Biopharma30.30%STTKShattuck Labs8.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANLAdlai Nortye12740.00 millionN/ANot OptionableCRDFCardiff Oncology2068.37 million63.11 millionOptionableIMMXImmix Biopharma954.41 million37.92 millionOptionableSTTKShattuck Labs10076.68 million69.94 millionOptionableCRDF, IMMX, ANL, and STTK HeadlinesRecent News About These CompaniesShattuck Labs (NASDAQ:STTK) Cut to Hold at Wall Street ZenMay 23, 2026 | americanbankingnews.comShattuck Labs: Priced As If Risk Was Not A Part Of The EquationMay 22, 2026 | seekingalpha.comShattuck Labs (NASDAQ:STTK) Insider Sells $14,244.32 in StockMay 15, 2026 | insidertrades.comWe're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn RateMay 11, 2026 | finance.yahoo.comShattuck Labs (NASDAQ:STTK) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPSMay 8, 2026 | marketbeat.comWedbush Forecasts Strong Price Appreciation for Shattuck Labs (NASDAQ:STTK) StockMay 8, 2026 | marketbeat.comShattuck Labs, Inc.: Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business HighlightsMay 7, 2026 | finanznachrichten.deShattuck Labs Reports First Quarter 2026 Financial Results and Recent Business HighlightsMay 7, 2026 | globenewswire.comCantor Fitzgerald Initiates Coverage of Shattuck Labs (STTK)May 1, 2026 | insidermonkey.comShattuck Labs (STTK) to Release Earnings on ThursdayApril 30, 2026 | marketbeat.comShattuck Labs (STTK) price target increased by 24.00% to 12.65April 29, 2026 | msn.comCantor Fitzgerald initiates coverage of Shattuck Labs (STTK) with overweight recommendationApril 28, 2026 | msn.comShattuck Labs: Surviving In An AI World Is Going To Be ToughMarch 27, 2026 | seekingalpha.comShattuck Labs (STTK) price target increased by 37.93% to 10.20March 27, 2026 | msn.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Shattuck Labs (STTK), Oruka Therapeutics (ORKA) and Option Care Health (OPCH)March 14, 2026 | theglobeandmail.comShattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business ...March 5, 2026 | caledonianrecord.comCShattuck Labs Advances SL-325 Clinical Trials, Reports Financial Results for Q4 and Full Year 2025March 5, 2026 | quiverquant.comQShattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business HighlightsMarch 5, 2026 | globenewswire.comShattuck Labs Announces Participation in Upcoming March Investor ConferencesFebruary 25, 2026 | globenewswire.comShattuck Labs Sets Earlier Date for 2026 Annual MeetingFebruary 21, 2026 | theglobeandmail.comShattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology SymposiumFebruary 6, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRDF, IMMX, ANL, and STTK Company DescriptionsAdlai Nortye NASDAQ:ANL$11.94 +0.64 (+5.66%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$12.02 +0.08 (+0.67%) As of 05/29/2026 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.Cardiff Oncology NASDAQ:CRDF$1.90 +0.06 (+3.26%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$1.86 -0.04 (-2.00%) As of 05/29/2026 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Immix Biopharma NASDAQ:IMMX$9.00 +0.16 (+1.81%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$8.99 -0.01 (-0.06%) As of 05/29/2026 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Shattuck Labs NASDAQ:STTK$5.95 -0.02 (-0.34%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$5.94 0.00 (-0.08%) As of 05/29/2026 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem MongoDB's AI Advantage Is Starting to Show Up in Results Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds These 3 Software Stocks Are Buying Back Shares Hand Over Fist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
